| domain | evidence-based finding | suggested ontology identifiers/terms | evidence limitations |
|---|---|---|---|
| Nomenclature / disease scope | Thymic neuroendocrine neoplasms are rare thymic epithelial tumors; available evidence groups them into well-differentiated carcinoid tumors and high-grade neuroendocrine carcinomas (small-cell and large-cell types). The exact label “thymic neuroendocrine carcinoma” is used inconsistently across sources, so knowledge-base entries should preserve both the broad thymic NEN umbrella and the high-grade NEC subset (pqac-00000000, pqac-00000001). | MONDO: **MONDO_0020516** thymic neuroendocrine carcinoma; MONDO: thymic large cell neuroendocrine carcinoma **MONDO_0003047**; MONDO: thymus small cell carcinoma **MONDO_0004122**; NCIT/MeSH IDs: unavailable here | WHO-class wording is partly inferred from review-level summaries; no directly retrieved WHO monograph text or full thymus-specific pathology paper in context. |
| Resource level | Most facts here are aggregated disease-level literature/guideline/trial-registry findings rather than individual EHR-derived observations (pqac-00000000, pqac-00000002). | Evidence type tag: aggregated literature / registry / trial registry | Not a patient-level dataset. |
| Anatomy | Primary site is the **thymus** in the **anterior mediastinum**; thymic NETs are described as aggressive mediastinal tumors (pqac-00000001). | UBERON: thymus **UBERON:0002370**; UBERON: mediastinum **UBERON:0003406**; anatomy qualifier: anterior mediastinum ID unavailable here | “Anterior mediastinum” ontology accession not verified in retrieved context. |
| Principal phenotype: mass effect / thoracic presentation | Approximate/extrapolated: anterior mediastinal tumors commonly present with local mass-effect symptoms such as cough, chest pain, dyspnea, or may be incidentally detected; this is consistent with thymic epithelial tumor guidance but not directly quantified for thymic NEC in retrieved context (pqac-00000000). | HPO suggestions: Chest pain **HP:0100749**; Cough **HP:0012735**; Dyspnea **HP:0002094**; Mediastinal mass ID unavailable here | Largely extrapolated from thymic epithelial tumor practice and thoracic oncology, not directly enumerated in retrieved thymic NEC abstracts. |
| Principal phenotype: endocrine syndromes | About **50%** of thymic NET manifestations were reported in one review summary as associated with endocrinopathies, including **Cushing syndrome** and acromegaly; endocrine secretion can strongly affect quality of life (pqac-00000001). | HPO: Cushing syndrome **HP:0002664**; Hypercortisolism **HP:0000846**; Ectopic ACTH secretion ID unavailable here | Figure comes from a narrative review summary and may reflect pooled historical literature; not necessarily specific to only high-grade NEC. |
| Principal phenotype: hereditary association | Thymic NETs/carcinoids are associated with **MEN1**; available sources note this association and describe prophylactic thymectomy/surveillance questions in MEN1 populations (pqac-00000001, pqac-00000002). | MONDO: multiple endocrine neoplasia type 1 ID unavailable here; OMIM MEN1 syndrome ID not verified here; gene **MEN1** (HGNC:7010) | MEN1 association is strongest for thymic carcinoid / thymic NET broadly, not proven for every thymic NEC subtype. |
| Pathology / neuroendocrine differentiation markers | Neuroendocrine tumors are typically confirmed by neuroendocrine-marker expression; practical markers for ontology-ready annotation include **synaptophysin**, **chromogranin A**, and **INSM1**; cytokeratin supports epithelial nature; **Ki-67** helps grading/proliferation assessment. General NEN reviews also note chromogranin A and synaptophysin as diagnostic markers (pqac-00000001). | Proteins/genes: **SYP**, **CHGA**, **INSM1**, broad-spectrum keratins (**KRT8/KRT18/KRT19** approximate), **MKI67**; NCIT marker terms: unavailable here | Synaptophysin/chromogranin use is strongly standard but not directly enumerated in a thymus-specific primary study in retrieved context; **INSM1** is included as current practice but extrapolated. |
| Pathology / SSTR biology | Somatostatin receptor subtypes are expressed in neuroendocrine neoplasms, with **SSTR2A** particularly prominent; a study across NENs concluded NECs may be candidates for somatostatin-analogue targeting and that SSTR2A can serve as a biomarker of neuroendocrine differentiation (pqac-00000000). | Gene/protein: **SSTR2**; IHC marker: SSTR2A; CHEBI class: somatostatin analogues | Not thymus-specific; based on mixed-site NENs/NECs. |
| Molecular distinction | Current understanding supports a biologic split: **MEN1-associated / carcinoid-like** disease for well-differentiated thymic NETs versus **TP53/RB1-altered high-grade NEC-like** biology for poorly differentiated NECs. Open Targets currently shows no direct curated target evidence rows for MONDO_0020516, so TP53/RB1 annotation should be flagged as approximate/extrapolated from large-cell NEC and general NEC biology (pqac-00000000, pqac-00000001). | Gene terms: **MEN1**, **TP53**, **RB1**, possibly **CDKN2A**; GO: regulation of cell cycle **GO:0051726**, apoptotic process **GO:0006915** | Strong caveat: TP53/RB1 evidence in context is not thymus-specific primary sequencing for MONDO_0020516; direct molecular data remain sparse. |
| Metastatic pattern | Thymic NETs are described as aggressive and capable of metastasizing to **liver, lymph nodes, bone, lung, and brain** (pqac-00000001). | HPO suggestions: Hepatic metastases **HP:0007340**; Lymph node metastases **HP:0005276**; Bone metastases ID unavailable here; Brain metastases ID unavailable here | Review-level statement; site-specific frequencies not available in retrieved context. |
| Epidemiology / rarity | Thymic neuroendocrine tumors are ultra-rare. In SEER-based analysis of **2000-2018**, **263** thymic NET patients were identified; another recent epidemiology paper confirms thymic NETs are part of the rare TET spectrum (pqac-00000000). | MONDO rarity annotation applicable; Orphanet ID unavailable here | No precise population incidence per 100,000 for thymic NET alone in retrieved context. |
| Second malignancy risk | In SEER analysis, thymic NET patients had increased risk of second malignancies with **SIR 1.73 (95% CI 1.13-2.54)**; **19/263** thymic NET patients developed second malignancies and age at diagnosis was a significant risk factor (pqac-00000000). | HPO/NCIT terms for second primary malignancy: ID unavailable here | Applies to thymic NET broadly, not only high-grade NEC. |
| Diagnostics / imaging | Approximate/current practice: diagnosis relies on thoracic imaging plus tissue biopsy; functional imaging may include somatostatin-receptor imaging when SSTR-positive disease is suspected, especially for therapeutic selection (pqac-00000000). | Rad/biomarker suggestions: CT chest; MRI as needed; SSTR PET/CT (e.g., Ga-68 DOTATATE, CHEBI/NCIT IDs unavailable here) | Imaging workflow is partly extrapolated from general NET and thymic epithelial tumor practice; no thymus-specific imaging trial in retrieved context. |
| Diagnostics / histology | Histologic confirmation should record neuroendocrine morphology, epithelial differentiation, and proliferative index. For ontology curation, capture tumor type (carcinoid vs small-cell NEC vs large-cell NEC), marker panel, necrosis, and Ki-67/mitotic activity (pqac-00000000, pqac-00000001). | NCIT disease classes unavailable here; genes/proteins: **MKI67**, **SYP**, **CHGA**, **INSM1**, keratins | Detailed cutoff values and consensus thymus-specific grading text were not present in retrieved context. |
| Treatment classes | **Surgery** remains the principal treatment for resectable thymic epithelial tumors; systemic options across thymic NET/NEN practice may include **chemotherapy**, **somatostatin analogues**, **everolimus**, **temozolomide-based regimens/CAPTEM**, **PRRT**, and occasionally **immunotherapy**, but much of this is extrapolated from non-thymic or mixed thoracic NET literature (pqac-00000000). | NCIT intervention suggestions: Surgical Resection; Chemotherapy; Somatostatin Analog Therapy; Everolimus Therapy; Temozolomide Regimen; Capecitabine/Temozolomide Regimen; Peptide Receptor Radionuclide Therapy; Immune Checkpoint Inhibitor Therapy | Direct thymus-specific comparative efficacy data were not retrieved; several treatment labels are extrapolated/current-practice rather than proven in thymic NEC. |
| Current real-world / trial implementations | Ongoing or recent studies relevant to thymic NET include **NCT06121271** (phase II Lu-177 DOTATATE in unlicensed indications; planned enrollment 110), **NCT07429851** (observational comparison of thymic/pulmonary/pancreatic well-differentiated high-grade NETs; enrollment 34), and **NCT05061784** (routine transcervical thymectomy in MEN1; completed, n=7) (pqac-00000002). | ClinicalTrials.gov: **NCT06121271**, **NCT07429851**, **NCT05061784** | Trials are not specific to thymic neuroendocrine carcinoma alone; some focus on NETs or MEN1 prevention rather than established NEC treatment. |
| Prevention / MEN1 surveillance | In MEN1, prophylactic or routine **transcervical thymectomy** at time of parathyroid surgery has been used to reduce thymic carcinoid risk, but efficacy data are described as scarce; surveillance remains important (pqac-00000002). | Preventive intervention: transcervical thymectomy; genetic counseling; MEN1 surveillance protocol IDs unavailable here | Evidence base is limited, observational, and focused on MEN1-associated thymic carcinoid risk rather than sporadic thymic NEC. |
| Prognosis / natural history | Available sources characterize thymic NETs as **aggressive** with metastatic potential and relatively limited chemotherapy responsiveness (pqac-00000001). | HPO suggestions: Neoplasm metastasis **HP:0002664** approximate broad cancer term unavailable; progressive disease term unavailable here | No robust retrieved survival percentages specific to MONDO_0020516. |
| Cell/tissue ontology suggestions | Tumor likely arises from **thymic epithelial/neuroendocrine differentiated** cells within thymic tissue; annotate epithelial tumor with neuroendocrine differentiation (pqac-00000001). | CL: neuroendocrine cell term approximate **CL:0000165**; thymic epithelial cell term ID unavailable here; GO CC: nucleus/cytoplasm markers not specific | Precise thymic cell-of-origin remains uncertain; CL terms not fully verified in retrieved context. |
| Model systems | No disease-specific validated model organisms or cell-line resources were identified in retrieved context for thymic neuroendocrine carcinoma; use “not established / not retrieved” in the knowledge base. | Model organism/resource IDs unavailable | Important knowledge gap. |


*Table: This table provides an ontology-ready summary of thymic neuroendocrine carcinoma/neoplasms, emphasizing what is directly supported in the retrieved evidence versus what is approximate or extrapolated. It is designed to help populate structured disease knowledge-base fields while preserving uncertainty.*